A Phase IIb Study to Determine the Safety and Efficacy of Candidate INfluenza Vaccine MVA-NP+M1 in Combination With Licensed InaCTivated inflUenza Vaccine in adultS Aged 65 Years and Above
Latest Information Update: 13 Dec 2023
At a glance
- Drugs VTP 100 (Primary) ; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Therapeutic Use
- Acronyms INVICTUS
- Sponsors Barinthus Biotherapeutics
- 17 Nov 2019 Planned number of patients changed from 2048 to 2030.
- 20 Nov 2018 Status changed from recruiting to discontinued due to change to recommended season flu vaccine in UK
- 19 Jan 2018 According to a Vaccitech media release, first round of participants has been recruited with over 862 people, this marks the end of the first phase of the trial, which will open again for new participants at the start of the winter flu vaccination programme in late 2018.